Mason Street Advisors LLC purchased a new position in Amedisys Inc. (NASDAQ:AMED) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,488 shares of the company’s stock, valued at approximately $277,000.
Several other large investors have also recently bought and sold shares of the company. Acrospire Investment Management LLC bought a new position in shares of Amedisys during the first quarter worth approximately $108,000. Invictus RG raised its position in shares of Amedisys by 152.7% in the second quarter. Invictus RG now owns 2,813 shares of the company’s stock worth $142,000 after buying an additional 1,700 shares in the last quarter. PineBridge Investments L.P. raised its position in shares of Amedisys by 2.9% in the second quarter. PineBridge Investments L.P. now owns 3,560 shares of the company’s stock worth $180,000 after buying an additional 101 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Amedisys by 21.6% in the second quarter. Teacher Retirement System of Texas now owns 3,780 shares of the company’s stock worth $191,000 after buying an additional 672 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in shares of Amedisys during the second quarter worth approximately $204,000. 91.45% of the stock is owned by institutional investors.
Shares of Amedisys Inc. (NASDAQ:AMED) opened at 45.63 on Friday. The stock’s 50 day moving average price is $48.02 and its 200 day moving average price is $49.82. Amedisys Inc. has a one year low of $31.16 and a one year high of $55.16. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of 39.92 and a beta of 0.96.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, meeting analysts’ consensus estimates of $0.42. The company had revenue of $360 million for the quarter, compared to analyst estimates of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.43 earnings per share. On average, equities analysts anticipate that Amedisys Inc. will post $1.69 earnings per share for the current fiscal year.
A number of research analysts have recently commented on the company. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $57.00 price objective on the stock in a report on Tuesday, July 5th. Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $57.00 to $55.00 in a report on Wednesday, August 3rd. Jefferies Group reissued a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Finally, Stephens assumed coverage on Amedisys in a report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $51.75.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.